Journal of Pain and Symptom Management
Volume 23, Issue 5 , Pages 442-447 , May 2002

An Open-Label, Crossover Trial of Mirtazapine (15 and 30 mg) in Cancer Patients with Pain and Other Distressing Symptoms

  • Dale E Theobald, PhD, MD

      Affiliations

    • Oncology Symptom Control & Research, Community Cancer Care, Indianapolis, IN, USA
    • Oncology Symptom Control Research, Methodist Health Foundation, Indianapolis, IN, USA
    • Corresponding Author InformationAddress reprint requests to: Dale E. Theobald, PhD, MD, Oncology Symptom Control Research, Community Cancer Care, Inc., 115 W. 19th Street, Indianapolis, IN 46202, USA
    • ,
  • Kenneth L Kirsh, MS

      Affiliations

    • Indiana University Purdue University, Indianapolis, IN, USA
    • ,
  • Elizabeth Holtsclaw, BA

      Affiliations

    • Oncology Symptom Control & Research, Community Cancer Care, Indianapolis, IN, USA
    • ,
  • Kathleen Donaghy, PhD

      Affiliations

    • Oncology Symptom Control & Research, Community Cancer Care, Indianapolis, IN, USA
    • ,
  • Steven D Passik, PhD

      Affiliations

    • Oncology Symptom Control & Research, Community Cancer Care, Indianapolis, IN, USA

,Accepted 8 August 2001.

References 

  1. Derogatis LR, Morrow GR, Fetting J, et al.  The prevalence of psychiatric disorders among cancer patients. JAMA. 1983;249:751–757
  2. Wells KB, Stewart A, Hayes RD, et al.  The Functioning and Well-being of Depressed Patients (Results from the Medical Outcomes Study). JAMA. 1989;262:914–919
  3. Simon J, Glazer W. Carving in and Keeping Mental Health Care in the Managed Care Setting. Psychiatric Services. 1995;46(11):1119–1120
  4. Portenoy R, Thaler H, Kornblith A, et al.  The Memorial Symptom Assessment Scale (An instrument for the evaluation of symptom prevalence, characteristics, and distress). Eur J Cancer. 1994;30A(9):1326–1336
  5. Holland JC, Romano SJ, Heiligenstein JH, et al.  A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-Oncology. 1998;7:291–300
  6. Passik SD, Theobald DE, Lundberg J, et al. Initial results of an investigation of the effects of olanzapine for the relief of opioid-induced nausea in cancer pain patients, Midwest Pain Society 23rd Scientific Meeting, March 12–13, 1999, Chicago, IL.
  7. Passik SD, Theobald DE, Lundberg J, Donaghy K, Holtsclaw E, Kirsh K. The initial experiences with anti-depressant algorithm in a community based oncology clinic. Pan American Congress of Psychosocial and Behavioral Oncology, October 20–23, 1999, New York, NY.
  8. Breitbart W. Psychotropic adjuvant analgesics for cancer pain. Psycho-oncology. 1992;1:133–145
  9. Nutt D. Mirtazapine (pharmacology in relation to adverse events). Acta Psychiatrica Scandinavia. 1997;96(Suppl 391):31–37
  10. Pederson L, Klysner R. Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapine. Int Clin Psychopharmacol. 1997;12:59–60
  11. Richelson E. Pharmacology of antidepressants-characteristics (of the ideal drug). Mayo Clin Proc. 1994;69(11):1069–1081
  12. Zung W. Depression in the normal aged. Psychosomatics. 1967;7:287–292
  13. Zung W. Factors influencing the self-rating depression scale. Arch Gen Psych. 1967;16:543–547
  14. Dugan W, McDonald M, Passik S, et al.  Use of the zung self-rating depression scale in cancer patients (Feasibility as a screening tool). Psycho-Oncology. 1998;7:483–493
  15. Tate D, Forchheimer M, Maynard F, et al.  Comparing two measures of depression in spinal cord injury. Rehabilitation Psychology. 1993;38:53–61
  16. Cella D, Bonomi A, Lloyd S, et al.  Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199–220
  17. Cella D, Tulsky D, Gray G, et al.  The functional assessment of cancer therapy scale (Development and validation). J Clin Oncology. 1993;11:570–579
  18. Brady M, Cella D, Mo F, et al.  Reliability and validity of the functional assessment of cancer therapy breast quality of life instrument. J Clin Oncology. 1997;15:974–986
  19. Yella S, Cella D, Webster K, et al.  Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT-G) measurement system. J Pain and Symptom Manage. 1997;13:63–74
  20. Winstead-Fry P, Schultz A. Psychometric analysis of the functional assessment of cancer therapy-general (FACT-G) scale in a rural sample. Cancer. 1997;79:2446–2452
  21. Fishman B, Pastermak S, Wallenstein S, et al.  The memorial pain assessment card (a valid instrument for the assessment of cancer pain). Cancer. 1987;60:1151–1157
  22. Passik SD, Lundberg JL, Rosenfeld B, et al.  Factor analysis of the Zung self-rating depression scale in a large ambulatory oncology sample. Psychosomatics. 2000;41:121–127

PII: S0885-3924(02)00381-0

Journal of Pain and Symptom Management
Volume 23, Issue 5 , Pages 442-447 , May 2002

Article Tools